We are pleased to announce that the 12-month follow-up data of our clinical study ‘Treatment with a polycaprolactone (PCL)-based bioresorbable urethral bulking agent for mild to moderate stress urinary incontinence (SUI)’ has been accepted for Oral Presentation (O14) on Thursday 25th of April 14:15-15:30h at the upcoming UKCS Meeting, 24-26 April 2019 in Manchester, United Kingdom.

Stress urinary incontinence (SUI) is treatable, it is not a taboo. It is imperative to seek advice and help for any condition which negatively affects your quality of life, such as SUI.

A major milestone, AQLANE Medical has received EN ISO 13485:2016 certification for its Quality Management System (QMS).

We are pleased to announce that our 6-month clinical data abstract has been accepted for Poster Presentation at the upcoming ICS 2018 Meeting 28-31 August in Philadelphia, USA.

The Urolon™ European Clinical Trial reaches another milestone; all patients have now completed their 12-month follow-up visit.